Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) shares traded down 7.2% during trading on Thursday following a dissappointing earnings announcement. The stock traded as low as $21.80 and last traded at $23.13. 1,094,046 shares were traded during trading, a decline of 38% from the average session volume of 1,757,342 shares. The stock had previously closed at $24.92.
The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%.
Wall Street Analyst Weigh In
A number of research analysts have commented on the company. Needham & Company LLC boosted their target price on Cellebrite DI from $21.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. boosted their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Craig Hallum increased their price objective on Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $22.14.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. NewEdge Advisors LLC boosted its position in Cellebrite DI by 600.7% during the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock worth $86,000 after purchasing an additional 3,352 shares during the period. PEAK6 LLC acquired a new stake in shares of Cellebrite DI in the fourth quarter worth $707,000. Jump Financial LLC boosted its holdings in shares of Cellebrite DI by 9.0% during the 4th quarter. Jump Financial LLC now owns 141,000 shares of the company’s stock worth $3,106,000 after buying an additional 11,609 shares during the period. Barclays PLC grew its stake in Cellebrite DI by 69.1% in the 4th quarter. Barclays PLC now owns 445,795 shares of the company’s stock valued at $9,821,000 after buying an additional 182,138 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Cellebrite DI by 7.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,630,439 shares of the company’s stock worth $35,919,000 after acquiring an additional 115,939 shares during the period. 45.88% of the stock is owned by institutional investors.
Cellebrite DI Stock Performance
The stock has a market cap of $4.47 billion, a price-to-earnings ratio of -14.00, a price-to-earnings-growth ratio of 3.72 and a beta of 1.47. The stock’s 50-day simple moving average is $22.57 and its two-hundred day simple moving average is $19.09.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories
- Five stocks we like better than Cellebrite DI
- How to Plot Fibonacci Price Inflection Levels
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Short Selling: How to Short a Stock
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- What Are Dividend Challengers?
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.